From the Research
Intravenous (IV) ozone therapy is not recommended for treating multiple sclerosis (MS). There is no reliable scientific evidence supporting its effectiveness or safety for MS treatment. The standard treatments for MS include FDA-approved medications such as interferon beta preparations (Avonex, Rebif, Betaseron), glatiramer acetate (Copaxone), natalizumab (Tysabri), fingolimod (Gilenya), and others that have been rigorously tested in clinical trials 1. These medications work by modulating the immune system to reduce inflammation and slow disease progression. IV ozone therapy, which involves introducing ozone gas into the bloodstream, lacks the scientific validation these approved treatments have. Additionally, IV ozone therapy carries potential risks including air embolism, blood clotting issues, and oxidative stress damage.
Some of the key considerations in MS treatment include:
- The use of disease-modifying therapies to reduce relapse rates and slow disease progression 2, 3, 4
- The importance of individualizing treatment plans based on patient preference, tolerability, and disease activity 1, 5
- The need for ongoing monitoring and adjustment of treatment plans to optimize outcomes 1, 5
If you have MS, it's essential to work with a neurologist specializing in MS to develop a treatment plan using evidence-based approaches rather than pursuing unproven alternative therapies like IV ozone. The most recent and highest quality study on MS treatment, published in 2020, highlights the efficacy and safety of interferon beta preparations and other FDA-approved medications for MS treatment 1. Therefore, IV ozone therapy should not be considered a viable treatment option for MS, and patients should instead focus on established, evidence-based treatments.